Pseudochylothorax
Updates to Article Attributes
Pseudochylothorax, also known as a pseudochylous effusion, chyliform effusion, cholesterol effusion, or cholesterol pleurisy, is a rare cause of pleural effusion due to the accumulation of a cholesterol crystal-rich fluid within the pleural space.
Epidemiology
The exact incidence of pseudochylothorax is unknown, however it is thought to be very rareuncommon 1,2. Indeed, the literature reports less than 200 cases 3.
Clinical presentation
Patients generally present with a slowly progressive course of varying degrees of respiratory distress and chest pain, depending on the amount of fluid that has accumulated 1,2,4,5.
Pathology
The pathogenesis of pseudochylothoraces is yet to be fully elucidated 2,4,5. Generally, pseudochylothoraces are most often a complication or evolution of a chronic exudative pleural effusions, typically associated with a fibrotic and thickened pleura 2,4,5. The most common aetiologies are Howevertuberculosis and rheumatoid arthritis, with far less common causes including neoplasm (e.g. lung cancer) and other infections (e.g. syphilis, echinococcosis) 1,2,4,5. , although often considered to require chronicity and , there are relatively recent case reports of more rapid-onset pleural thickening to developpseudochylothoraxpseudochylothoraces occurring in the absence of significant pleural thickening or chronicity 2,4,5.
Aetiology
The most common aetiologies are tuberculosis and rheumatoid arthritis 21,2,4,5. Other far less common causes include neoplasm (e.g. lung cancer) and other infections (e.g. syphilis, echinococcosis) 1,2,4,5.
Markers
The fluid in a pseudochylothorax is an exudate, typically with a high cholesterol content 5. A pleural fluid-to-serum cholesterol ratio of >1 is diagnostic, and differentiates it from a similarly appearing chylothorax 5.
Radiographic features
Pseudochylothoraces can be appreciated on any form of conventional chest imaging, such as plain radiograph or CT. Typically, they are unilateral with features that are indistinguishable from those of any other pleural effusion 3,5. In most cases, they are associated with ipsilateral pleural thickening 3,5.
Treatment and prognosis
A pseudochylothorax should be drained if symptomatic 2,5. Otherwise, the exact management strategy will depend on underlying aetiology 2,5. For example, in pseudochylothoraces secondary to rheumatoid arthritis, aggressive management of the rheumatoid arthritis often resulted in improvements of pleural collections 2,5.
History and etymology
Pseudochylothorax was first described by Bruce F Weems, an American physician, in 1918 6.
-<p><strong>Pseudochylothorax</strong>, also known as a <strong>pseudochylous effusion</strong>, <strong>chyliform effusion</strong>, <strong>cholesterol effusion</strong>, or <strong>cholesterol pleurisy</strong>, is a rare cause of <a href="/articles/pleural-effusion">pleural effusion</a> due to the accumulation of a cholesterol crystal-rich fluid within the <a href="/articles/intrapleural-space">pleural space</a>.</p><h4>Epidemiology</h4><p>The exact incidence of pseudochylothorax is unknown, however it is thought to be very rare <sup>1,2</sup>. Indeed, the literature reports less than 200 cases <sup>3</sup>.</p><h4>Clinical presentation</h4><p>Patients generally present with a slowly progressive course of varying degrees of respiratory distress and chest pain depending on the amount of fluid that has accumulated <sup>1,2,4,5</sup>.</p><h4>Pathology</h4><p>The pathogenesis of pseudochylothoraces is yet to be elucidated <sup>2,4,5</sup>. Generally, pseudochylothoraces are most often a complication or evolution of a chronic exudative <a title="Pleural effusions" href="/articles/pleural-effusion">pleural effusions</a>, typically associated with a fibrotic and <a title="Pleural thickening" href="/articles/pleural-thickening">thickened pleura</a> <sup>2,4,5</sup>. The most common aetiologies are <a title="Tuberculosis" href="/articles/tuberculosis">tuberculosis</a> and <a title="Rheumatoid arthritis" href="/articles/rheumatoid-arthritis">rheumatoid arthritis</a>, with far less common causes including neoplasm (e.g. <a title="Lung cancer" href="/articles/lung-cancer-3">lung cancer</a>) and other infections (e.g. <a title="Syphilis" href="/articles/syphilis">syphilis</a>, <a title="Echinococcosis" href="/articles/hydatid-disease">echinococcosis</a>) <sup>1,2,4,5</sup>. However, although often considered to require chronicity and <a title="Pleural thickening" href="/articles/pleural-thickening">pleural thickening</a> to develop, there are recent case reports of more rapid-onset pseudochylothorax occurring in the absence of significant <a href="/articles/pleural-thickening">pleural thickening</a> <sup>2,4,5</sup>.</p><h5>Markers</h5><p>The fluid in a pseudochylothorax is an exudate, typically with a high cholesterol content <sup>5</sup>. A pleural fluid-to-serum cholesterol ratio of >1 is diagnostic, and differentiates it from a similarly appearing <a title="Chylothorax" href="/articles/chylothorax">chylothorax</a> <sup>5</sup>.</p><h4>Radiographic features</h4><p>Pseudochylothoraces can be appreciated on any form of conventional chest imaging, such as plain radiograph or CT. Typically, they are unilateral with features that are indistinguishable from those of any other <a title="Pleural effusion" href="/articles/pleural-effusion">pleural effusion</a> <sup>3,5</sup>. In most cases, they are associated with ipsilateral <a href="/articles/pleural-thickening">pleural thickening</a> <sup>3,5</sup>.</p><h4>Treatment and prognosis</h4><p>A pseudochylothorax should be drained if symptomatic <sup>2,5</sup>. Otherwise, the exact management strategy will depend on underlying aetiology <sup>2,5</sup>. For example, in pseudochylothoraces secondary to <a title="Rheumatoid arthritis" href="/articles/rheumatoid-arthritis">rheumatoid arthritis</a>, aggressive management of the rheumatoid arthritis often resulted in improvements of pleural collections <sup>2,5</sup>.</p><h4>History and etymology</h4><p>Pseudochylothorax was first described by <strong>Bruce F Weems</strong> in 1918 <sup>6</sup>.</p>- +<p><strong>Pseudochylothorax</strong>, also known as a <strong>pseudochylous effusion</strong>, <strong>chyliform effusion</strong>, <strong>cholesterol effusion</strong>, or <strong>cholesterol pleurisy</strong>, is a rare cause of <a href="/articles/pleural-effusion">pleural effusion</a> due to the accumulation of a cholesterol crystal-rich fluid within the <a href="/articles/intrapleural-space">pleural space</a>.</p><h4>Epidemiology</h4><p>The exact incidence of pseudochylothorax is unknown, however it is thought to be very uncommon <sup>1,2</sup>. Indeed, the literature reports less than 200 cases <sup>3</sup>.</p><h4>Clinical presentation</h4><p>Patients generally present with a slowly progressive course of varying degrees of respiratory distress and chest pain, depending on the amount of fluid that has accumulated <sup>1,2,4,5</sup>.</p><h4>Pathology</h4><p>The pathogenesis of pseudochylothoraces is yet to be fully elucidated <sup>2,4,5</sup>. Generally, pseudochylothoraces are a complication or evolution of chronic exudative <a href="/articles/pleural-effusion">pleural effusions</a>, typically associated with a fibrotic and <a href="/articles/pleural-thickening">thickened pleura</a> <sup>2,4,5</sup>. However, there are relatively recent case reports of more rapid-onset pseudochylothoraces occurring in the absence of significant <a href="/articles/pleural-thickening">pleural thickening</a> or chronicity <sup>2,4,5</sup>.</p><h5>Aetiology</h5><p>The most common aetiologies are <a href="/articles/tuberculosis">tuberculosis</a> and <a href="/articles/rheumatoid-arthritis">rheumatoid arthritis</a> <sup>1,2,4,5</sup>. Other far less common causes include neoplasm (e.g. <a href="/articles/lung-cancer-3">lung cancer</a>) and other infections (e.g. <a href="/articles/syphilis">syphilis</a>, <a href="/articles/hydatid-disease">echinococcosis</a>) <sup>1,2,4,5</sup>.</p><h5>Markers</h5><p>The fluid in a pseudochylothorax is an exudate, typically with a high cholesterol content <sup>5</sup>. A pleural fluid-to-serum cholesterol ratio of >1 is diagnostic, and differentiates it from a similarly appearing <a href="/articles/chylothorax">chylothorax</a> <sup>5</sup>.</p><h4>Radiographic features</h4><p>Pseudochylothoraces can be appreciated on any form of conventional chest imaging, such as plain radiograph or CT. Typically, they are unilateral with features that are indistinguishable from those of any other <a href="/articles/pleural-effusion">pleural effusion</a> <sup>3,5</sup>. In most cases, they are associated with ipsilateral <a href="/articles/pleural-thickening">pleural thickening</a> <sup>3,5</sup>.</p><h4>Treatment and prognosis</h4><p>A pseudochylothorax should be drained if symptomatic <sup>2,5</sup>. Otherwise, the exact management strategy will depend on underlying aetiology <sup>2,5</sup>. For example, in pseudochylothoraces secondary to <a href="/articles/rheumatoid-arthritis">rheumatoid arthritis</a>, aggressive management of the rheumatoid arthritis often resulted in improvements of pleural collections <sup>2,5</sup>.</p><h4>History and etymology</h4><p>Pseudochylothorax was first described by <strong>Bruce F Weems</strong>, an American physician, in 1918 <sup>6</sup>.</p>
References changed:
- 1. Garcia-Zamalloa A, Ruiz-Irastorza G, Aguayo FJ, Gurrutxaga N. Pseudochylothorax. Report of 2 cases and review of the literature. (1999) Medicine. 78 (3): 200-7. <a href="https://doi.org/10.1097/00005792-199905000-00006">doi:10.1097/00005792-199905000-00006</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/10352651">Pubmed</a> <span class="ref_v4"></span>
- 2. Wrightson JM, Stanton AE, Maskell NA, Davies RJO, Lee YCG. Pseudochylothorax without pleural thickening: time to reconsider pathogenesis?. (2009) Chest. 136 (4): 1144-1147. <a href="https://doi.org/10.1378/chest.09-0445">doi:10.1378/chest.09-0445</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/19809057">Pubmed</a> <span class="ref_v4"></span>
- 3. Garcia-Zamalloa A. Pseudochylothorax, an unknown disease. (2010) Chest. 137 (4): 1004-5; author reply 1005. <a href="https://doi.org/10.1378/chest.09-2628">doi:10.1378/chest.09-2628</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/20371542">Pubmed</a> <span class="ref_v4"></span>
- 4. Hillerdal G. Chylothorax and pseudochylothorax. (1997) The European respiratory journal. 10 (5): 1157-62. <a href="https://www.ncbi.nlm.nih.gov/pubmed/9163662">Pubmed</a> <span class="ref_v4"></span>
- 5. Lama A, Ferreiro L, Toubes ME, Golpe A, Gude F, Álvarez-Dobaño JM, González-Barcala FJ, San José E, Rodríguez-Núñez N, Rábade C, Rodríguez-García C, Valdés L. Characteristics of patients with pseudochylothorax-a systematic review. (2016) Journal of thoracic disease. 8 (8): 2093-101. <a href="https://doi.org/10.21037/jtd.2016.07.84">doi:10.21037/jtd.2016.07.84</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/27621864">Pubmed</a> <span class="ref_v4"></span>
- 6. Weems BF. Cholesterohydrothorax, observations upon a case. (1918) The American Journal of the Medical Sciences. 156 (1): 20. <a href="https://doi.org/10.1097/00000441-191807000-00004">doi:10.1097/00000441-191807000-00004</a> <span class="ref_v4"></span>
Tags changed:
- cases
Systems changed:
- Chest